- Home
- LIEN vs AQST Comparison
LIEN vs AQST Comparison
Compare LIEN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- AQST
- Stock Information
- Founded
- LIEN 2021
- AQST 2004
- Country
- LIEN United States
- AQST United States
- Employees
- LIEN N/A
- AQST N/A
- Industry
- LIEN
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- AQST Health Care
- Exchange
- LIEN NYSE
- AQST Nasdaq
- Market Cap
- LIEN 234.6M
- AQST 254.1M
- IPO Year
- LIEN 2022
- AQST 2018
- Fundamental
- Price
- LIEN $10.10
- AQST $2.76
- Analyst Decision
- LIEN Hold
- AQST Strong Buy
- Analyst Count
- LIEN 1
- AQST 5
- Target Price
- LIEN N/A
- AQST $11.40
- AVG Volume (30 Days)
- LIEN 16.8K
- AQST 984.2K
- Earning Date
- LIEN 05-14-2025
- AQST 05-12-2025
- Dividend Yield
- LIEN 13.59%
- AQST N/A
- EPS Growth
- LIEN N/A
- AQST N/A
- EPS
- LIEN 0.93
- AQST N/A
- Revenue
- LIEN $21,665,753.00
- AQST $57,561,000.00
- Revenue This Year
- LIEN $102.44
- AQST N/A
- Revenue Next Year
- LIEN N/A
- AQST $39.51
- P/E Ratio
- LIEN $10.77
- AQST N/A
- Revenue Growth
- LIEN 81.56
- AQST 13.79
- 52 Week Low
- LIEN $9.71
- AQST $2.20
- 52 Week High
- LIEN $13.38
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- AQST 48.51
- Support Level
- LIEN N/A
- AQST $2.65
- Resistance Level
- LIEN N/A
- AQST $3.05
- Average True Range (ATR)
- LIEN 0.00
- AQST 0.16
- MACD
- LIEN 0.00
- AQST 0.00
- Stochastic Oscillator
- LIEN 0.00
- AQST 50.51
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.